Amgen's 7,297-Patient Olpasiran Trial Inherits a Higher Bar
Novartis drove the Lp(a) biomarker down without reducing cardiovascular events. That result shifts the burden onto Amgen's 7,297-patient olpasiran trial to show the mechanism works.
Amgen's olpasiran outcomes trial in 7,297 patients now faces a tougher test after Novartis lowered the Lp(a) biomarker without cutting cardiovascular events, leaving Amgen to prove the mechanism itself translates into clinical benefit.
Amgen (NASDAQ: AMGN) is running a 7,297-patient cardiovascular outcomes trial on olpasiran, its drug designed to lower lipoprotein(a). That trial just got harder to win — not because anything changed inside it, but because a rival got the biology it was aiming at and did not get the clinical result.
Novartis (NYSE: NVS) lowered the target biomarker without reducing cardiovascular events. In plain terms: the drug did what it was designed to do at the level of a blood measurement, and patients did not have fewer heart attacks or strokes for it. That is the single most damaging outcome a mechanism-driven programme can produce, because it moves the doubt from the molecule to the theory underneath it.
Why a Biomarker Miss Travels Across Companies
Lipoprotein(a), usually written Lp(a), is a genetically determined particle in the blood that has been linked to cardiovascular risk. Unlike LDL cholesterol, it barely responds to diet, exercise or statins. That made it one of the most attractive untouched targets in cardiology: a large population with elevated risk and no approved therapy aimed squarely at the cause.
The industry's bet was that if you could drive Lp(a) down far enough, events would follow — the same logic that made LDL-lowering one of the most commercially successful ideas in modern medicine. Drug developers call this a surrogate endpoint: a measurable proxy you accept as a stand-in for the outcome that actually matters.
Surrogates only hold if the causal chain is real. When Novartis moved the number and the events did not move with it, it raised the possibility that the chain has a break in it — that Lp(a) marks risk without driving enough of it to matter at the doses and durations being tested, or in the patient populations being enrolled. That doubt is not proprietary to Novartis. It attaches to every programme built on the same premise, and Amgen's is the largest one still reading out.
What Olpasiran Now Has to Show
Olpasiran uses RNA interference, an approach that silences the genetic instruction for making the target protein rather than blocking the protein after it exists. The distinction matters commercially — dosing is infrequent, which suits chronic prevention — but it does not exempt Amgen from the core question. If lowering Lp(a) does not lower events, the elegance of the delivery mechanism is beside the point.
So the trial's burden has shifted. Before the Novartis result, a positive readout would have confirmed an expected mechanism and opened a market. Now a positive readout has to do more work: it has to explain why olpasiran succeeded where the target was already hit and the events did not follow. The plausible answers — deeper or more durable suppression, longer follow-up, a differently selected patient group — are testable, but they are arguments Amgen will have to make with data rather than assume.
A neutral or ambiguous result carries a heavier penalty than it would have a year ago, because it would be the second reading pointing the same way. As GuruFocus framed it, olpasiran must now prove the mechanism can still deliver — the drug is being asked to defend a category, not just itself.
Where the Two Stocks Closed
Both companies drifted lower in the most recent session. Amgen last traded at 437.23, down 1.55% from a previous close of 444.12, within a day range of 435.00 to 441.85, as of the close on 4 September 2026. Novartis last traded at 159.99, down 1.90% from a previous close of 163.09, with a day range of 159.63 to 160.93.
Both moves were steeper than the broad market. The S&P 500 tracker (SPY) closed at $770.19, down 0.39%, and the Dow 30 tracker (DIA) at $534.08, down 0.53%, while the Nasdaq 100 tracker (QQQ) closed at $718.96, up 0.18%. Large-cap pharmaceutical weakness against a roughly flat tape is consistent with a sector digesting a scientific disappointment, though single sessions are noisy and neither move should be read as a verdict on the trial.
The Commercial Stakes Behind the Trial Size
The 7,297-patient enrolment is itself a statement of ambition. Cardiovascular outcomes trials are expensive and slow precisely because heart attacks and strokes accumulate over years, not months, and you need a large population to see a statistically credible difference. Companies do not fund studies at that scale for niche indications. The sizing implies Amgen expected a broad preventive market — the kind of chronic, guideline-driven prescribing base that supports revenue for a decade.
The sizing implies Amgen expected a broad preventive market — the kind of chronic, guideline-driven prescribing base that supports revenue for a decade.
That is what is now at risk in both directions. A clean win would establish Amgen as the first company to convert Lp(a) biology into clinical benefit, with a validated mechanism and limited competition — and it would revalidate the target for everyone else who has spent money there. A failure would do more than close one programme; it would suggest the industry has collectively misread how much of cardiovascular risk Lp(a) actually causes, and write off the investment across several pipelines at once.
What to Watch From Here
Three things will determine how this resolves. First, the detail underneath the Novartis result: how far the biomarker fell, in whom, and for how long. A shallow or short reduction is an easier problem for Amgen to distinguish itself from than a deep and sustained one. Second, whether Amgen or its trial investigators signal any change to the study's conduct or expected timing — protocol adjustments and enrolment commentary are the earliest tells in a programme under pressure. Third, whether analyst models start stripping olpasiran revenue out of Amgen's long-term forecasts. That process usually begins quietly, in probability-of-success assumptions, well before it shows up in a headline price target.
For now the position is straightforward to describe and hard to handicap. The biology that justified the bet has taken its first serious hit, the trial is large enough that its answer will be definitive either way, and one company is left carrying the question for a whole field.
Key facts
- AMGN last close: 437.23, -1.55% (as of 4 Sep 2026, 20:00 GMT)
- Trial size: 7,297 patients in Amgen's olpasiran cardiovascular outcomes study
- NVS last close: 159.99, -1.90% (as of 4 Sep 2026, 20:00 GMT)
- The setback: Novartis lowered the Lp(a) biomarker without reducing cardiovascular events
Frequently asked questions
What is olpasiran?
Olpasiran is Amgen's investigational drug designed to lower lipoprotein(a), or Lp(a), a genetically determined blood particle associated with cardiovascular risk. It uses RNA interference, which silences the genetic instruction to make the target rather than blocking the protein after it is produced. It is being tested in a cardiovascular outcomes trial enrolling 7,297 patients.
What did Novartis's result show?
Novartis lowered the target biomarker — Lp(a) — without producing a reduction in cardiovascular events. The drug achieved its intended biological effect on the blood measurement, but patients did not experience fewer heart attacks or strokes as a result. That combination raises questions about whether lowering Lp(a) reliably translates into clinical benefit.
Why does a Novartis failure affect Amgen?
Because both programmes rest on the same premise: that lowering Lp(a) reduces cardiovascular events. When one drug hits the biomarker target and the clinical outcome does not follow, the doubt shifts from the individual molecule to the underlying biological theory. Amgen's olpasiran must now demonstrate that the mechanism itself can deliver, not just that its drug works.
What is a surrogate endpoint?
A surrogate endpoint is a measurable proxy — often a blood marker — that drug developers accept as a stand-in for the clinical outcome that actually matters, such as a heart attack or stroke. Surrogates speed up trials, but they only hold if the causal link is genuine. When the surrogate moves and outcomes do not, the surrogate's validity is called into question.
Where did Amgen and Novartis shares last close?
Amgen last traded at 437.23, down 1.55% from a previous close of 444.12, within a day range of 435.00 to 441.85. Novartis last traded at 159.99, down 1.90% from a previous close of 163.09, in a range of 159.63 to 160.93. Both figures are as of the close on 4 September 2026.
Why is the trial so large?
Cardiovascular outcomes trials need large populations and long follow-up because heart attacks and strokes accumulate slowly. Detecting a statistically credible difference in event rates requires thousands of patients over years. A 7,297-patient enrolment signals that Amgen was targeting a broad preventive market rather than a narrow indication.
Sources
Photo: https://kaboompics.com/ · Pexels Licence — source
